Literature DB >> 19250125

QALYs: some challenges.

Erik Nord1, Norman Daniels, Mark Kamlet.   

Abstract

Mesh:

Year:  2009        PMID: 19250125     DOI: 10.1111/j.1524-4733.2009.00516.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  39 in total

Review 1.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.

Authors:  Meenakshi Bewtra; F Reed Johnson
Journal:  Patient       Date:  2013       Impact factor: 3.883

3.  Can quality or quality-of-life be defined?

Authors:  Ivan Barofsky
Journal:  Qual Life Res       Date:  2011-07-03       Impact factor: 4.147

4.  Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?

Authors:  Jonathan Karnon; Andrew Partington
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

5.  Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise.

Authors:  Seungjin Bae; Soook Lee; Eun Young Bae; Sunmee Jang
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

Review 6.  Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature.

Authors:  James Gallagher; Suzanne McCarthy; Stephen Byrne
Journal:  Int J Clin Pharm       Date:  2014-09-14

7.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

8.  Differences in EQ-5D-3L health state valuations among patients with musculoskeletal diseases, health care professionals and healthy volunteers.

Authors:  Anja Schwalm; You-Shan Feng; Jörn Moock; Thomas Kohlmann
Journal:  Eur J Health Econ       Date:  2014-10-05

Review 9.  Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Authors:  Cécile Gaujoux-Viala; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

10.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.